Black, S., Wilcock, G., Zavitz, K., Hendrix, S., & Swabb, E. (2008). Efficacy and safety of tarenflurbil, a selective a beta 42-lowering agent, in Alzheimer's disease (AD): A phase 2 trial of up to 24 months of treatment.
Citace podle Chicago (17th ed.)Black, S., G. Wilcock, K. Zavitz, S. Hendrix, a E. Swabb. Efficacy and Safety of Tarenflurbil, a Selective a Beta 42-lowering Agent, in Alzheimer's Disease (AD): A Phase 2 Trial of Up to 24 Months of Treatment. 2008.
Citace podle MLA (9th ed.)Black, S., et al. Efficacy and Safety of Tarenflurbil, a Selective a Beta 42-lowering Agent, in Alzheimer's Disease (AD): A Phase 2 Trial of Up to 24 Months of Treatment. 2008.
Upozornění: Tyto citace jsou generovány automaticky. Nemusí být zcela správně podle citačních pravidel..